Create a Free Account
or
Create a Free Account
or
| # | Filing Date | Period End Date | Type | Report Link |
|---|---|---|---|---|
| No Data found | ||||
| # | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
|---|
Relay Therapeutics shares are trading lower by 17.8% during Wednesday's session. The company priced its $200 million offering.
The gross proceeds from the offering, before deducting underwriting discounts and commissions and offering expenses, are expec...
Relay Therapeutics shares interim data for RLY-2608 from the ReDiscover study, showing a 57% clinical benefit rate. Oppenheimer...
B of A Securities analyst Jason Gerberry maintains Relay Therapeutics (NASDAQ:RLAY) with a Buy and raises the price target f...
JP Morgan analyst Eric Joseph maintains Relay Therapeutics (NASDAQ:RLAY) with a Overweight and lowers the price target from ...
Barclays analyst Peter Lawson maintains Relay Therapeutics (NASDAQ:RLAY) with a Overweight and raises the price target from ...
